On June 24, a delegation from City University of Hong Kong, including Professor Yang Mengsu, Vice President of the university, Dr. Zou Heng (Co-founder and CEO of Jingzhun Medical), Chief Technology Officer Dr. Li Zhi, Wang Shan (Deputy Director of the Precision Diagnosis and Treatment Technology Research Department at City University of Hong Kong), Guan Sen (Senior Manager, Research, Futian Institute), Professor Zhou Xiaoyu, Professor Liu Beilei, Dr. Yang Zihan, and Dr. Si Tongxu,visited Shenzhen Cell Valley for an exchange. The delegation was warmly received by Professor Shi Yuanyuan (Chairman and General Manager of Shenzhen Cell Valley), Wei Zheng (Director of the Administrative Department), Dr. Zhao Lijun (Head of the R&D Department), Dr. Fu Yuchen (Assistant to the Chairman), and Sun Rui (Head of the Marketing Department).

During the exchange, the three parties engaged in in-depth discussions on multiple dimensions, including the development of automated cell therapy equipment, clinical testing technologies, collaborative applications for major research projects, and business expansion. Fu Yuchen, Assistant to the Chairman, provided the visiting team with a detailed introduction to Shenzhen Cell Valley's strategic positioning in the field of gene therapy, the background of its founding team, core technology systems, recent R&D progress, production processes and quality control systems, as well as the latest achievements in clinical translation applications. The visiting team expressed high recognition for Shenzhen Cell Valley's profound technical expertise and innovative practices in the field of cell therapy.

At the symposium, Professor Shi Yuanyuan stated that Shenzhen Cell Valley has always adhered to the core mission of 'breaking through the' bottleneck 'technologies in the industry,' focusing on the field of cell and gene therapy, and is committed to building a comprehensive service system spanning from basic research to clinical applications. Leveraging its proprietary viral vector technology platform and GMP production system compliant with international standards, the company has established in-depth clinical collaborations with over 80 tertiary hospitals nationwide, accumulating extensive translational medicine experience in areas such as tumor immunotherapy and gene-modified cell therapy. The company's main cell products include CAR-T, CAR-NK, NK, MSC, and exosomes, with broad applications spanning hematologic malignancies, solid tumors, autoimmune diseases, neurodegenerative disorders, and anti-aging therapies. Professor Shi Yuanyuan emphasized that Shenzhen Cell Valley looks forward to deep collaboration with Professor Yang Mengsu's team and Jingzhun Biomedical, integrating clinical resources, patient data, and demand guidance to provide clinical perspectives and data support for major research project applications, as well as comprehensive cooperation in joint promotion of testing services and technology transfer.

Dr. Zou Heng introduced the core advantages of Jingzhun Biomedical as an innovative biotechnology enterprise. Founded by Professor Yang Mengsu, Vice President of City University of Hong Kong, Jingzhun Biomedical focuses on the research and development of innovative technologies for cancer prevention, early screening, diagnosis, and treatment, establishing a comprehensive testing technology platform covering the entire process. Jingzhun Biomedical demonstrates significant strengths in clinical testing services, standardized processes, and quality management. The company looks forward to deep collaboration with Shenzhen Cell Valley to jointly advance breakthroughs and expand the application of specific detection technologies.

Professor Zhou Xiaoyu highlighted the outstanding research achievements of City University of Hong Kong and Professor Yang Mengsu's team. City University of Hong Kong has maintained its position as the top university in Hong Kong for ten consecutive years in terms of research paper citations, while also ranking first in Hong Kong for nine straight years among the top 100 global universities with the most U.S. patents. Professor Yang Mengsu's team stated that they will provide advanced detection technologies and scientific support in the field of cell and gene research, lead the scientific design, and accelerate the joint application of major research projects by the three parties, injecting strong momentum into the collaboration.

The three parties reached a consensus on clinical testing, scientific research collaboration, and business expansion, with plans to be refined and implemented to jointly advance the achievement of cooperative objectives. This collaboration injects new momentum into Shenzhen Cell Valley in the field of cell and gene therapy, while also laying the foundation for in-depth cooperation among the three parties.